August 14 - CTI to Report 2008 Second Quarter Financial Results on August 18
August 12 - CTI Announces that the EORTC Completes Enrollment in Phase II Clinical Trial of Brostallicin as First-Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
August 5 - Craig W. Philips Takes Helm at CTI
July 22 - CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
July 15 - 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
June 18 - CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
More Press Releases
